➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Merck
Harvard Business School
AstraZeneca
Baxter

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,884,434


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,884,434 protect, and when does it expire?

Patent 6,884,434 protects NEUPRO and is included in one NDA.

This patent has forty-two patent family members in thirty countries.

Summary for Patent: 6,884,434
Title: Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
Abstract:A transdermal therapeutic system, comprising a backing layer inert to the components of the matrix, a self-adhesive matrix layer containing (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol in an effective amount and a protective foil or sheet to be removed prior to use, is characterised by a matrix that is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system having a solubility of .gtoreq.5% (w/w) for (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthaleno l, and said matrix is substantially free of inorganic silicate particulates.
Inventor(s): Muller; Walter (Neuwied, DE), Peck; James V. (Richmond, VA)
Assignee: LTS Lohmann Therapie-Systeme AG (Andernach, DE) Aderis Pharmaceuticals, Inc. (Richmond, VA)
Application Number:09/647,290
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,884,434
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 6,884,434

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,884,434

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 14 084Mar 30, 1998
PCT Information
PCT FiledMarch 18, 1999PCT Application Number:PCT/EP99/01795
PCT Publication Date:October 07, 1999PCT Publication Number: WO99/49852

International Family Members for US Patent 6,884,434

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 014778 ⤷  Try it Free
Austria 210973 ⤷  Try it Free
Australia 2934199 ⤷  Try it Free
Australia 746856 ⤷  Try it Free
Brazil 9909313 ⤷  Try it Free
Canada 2326630 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Baxter
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.